The Frequency of HBsAg in Pregnant Women from Eastern Mediterranean and Middle Eastern Countries: A Systematic Review and Meta-Analysis

Pooneh Malekifar¹, Mehran Babanejad ², Neda Izadi ³ and Seyed Moayed Alavian ⁴ *

¹Department of Epidemiology, Research Student Committee, School of Public Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran ²Social Development and Health Promotion Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran ³Research Student Committee, School of Public Health, Kermanshah University of Medical Sciences, Kermanshah, Iran ⁴Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, Iran  

*Corresponding author: Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, Iran. Email: editor@hepatmon.com

Received 2017 July 26; Revised 2018 July 20; Accepted 2018 July 21.

Abstract

Context: The present study aimed to determine the prevalence of HBsAg in pregnant women using available data in Eastern Mediterranean Region Office (EMRO) and Middle Eastern countries from 2000 to 2016.

Evidence Acquisition: Pubmed, ISI Web of Science, ScienceDirect, Ovid, Scopus, Google Scholar, and Persian databases were searched for related articles on the prevalence of HBsAg in pregnant women in EMRO and Middle Eastern countries. Heterogeneity was assessed based on Cochran’s Q-test results. However, since this test may fail to exactly identify true heterogeneity, it was complemented with Higgins and Thompson’s I².

Results: In general, the numbers of 49 articles (89 452 people) were included. Based on available data, the HBsAg prevalence in countries with at least one study conducted in them were 3.2% in Egypt, 1.3% in Iran, 4.3% in Jordan, 1.5% in Libya, 7.1% in Oman, 2% in Pakistan, 1% in Qatar, 2.6% in Saudi Arabia, 5.6% in Sudan, 4% in Tunisia, 2.8% in Turkey, 1.5% in United Arab Emirates, and 10.8% in Yemen.

Conclusions: The available data on the prevalence of HBsAg in pregnant women of EMRO and Middle East countries showed that there was a different pattern of HBsAg prevalence in studied countries. Although there were countries with low prevalence of HBsAg, the lowest frequency in our study was higher than the reported prevalence in developed countries.

Keywords: Prevalence, Hepatitis B, Eastern Mediterranean, Middle East, Meta-Analysis, Pregnant Women

1. Context

Hepatitis B virus (HBV) has infected more than one-third of the population around the world. It is estimated that more than 350 million people are chronic carriers of HBV, worldwide. HBV is one of the main causes of chronic hepatitis, with the disease progressing to hepatic cirrhosis, renal failure, or liver cancer in infected people (1, 2). Half of the infections with HBV, especially in countries with the moderate-to-high prevalence, occur in prenatal or early-childhood periods (3, 4) due to the high prevalence of hepatitis B surface antigen (HBsAg) among fertile women who transmit this infection to newborns (5). HBsAg is the main blood indicator of acute HBV infection, the existence of which is in the body for over 6 months indicates chronic infection (6).

Without any intervention or treatment for HBV infection in pregnant women, this infection will be transmitted to the fetus or newborns in 70% - 90% of cases, in which the mother’s hepatitis B e-antigen and HBsAg are both positive (7, 8), and in 10% of cases, in which only the HBsAg is positive (9, 10). Currently, the hepatitis B vaccine, that is highly reliable and effective in preventing the infection, is widely available to the public, especially pregnant women (11, 12). Nevertheless, HBV infection management during pregnancy is extremely difficult with respect to the risk of transmitting the infection to the fetus (11, 13). Screening programs for mothers aiming to identify those with positive HBsAg are implemented in many countries as a part of usual pregnancy examinations. If a mother is HBsAg positive, her neonate must receive hepatitis B immune globulin in order to decrease the chance of HBV vertical transmission (13). Although prophylaxis is effective in dimin-
ishing HBV infection transmission from the mother to the newborns, 3% - 13% of children born from HBsAg-positive mothers are still infected with HBsAg, a rate that is not negligible (13, 14).

The World Health Organization (WHO) has estimated the prevalence of HBV in the Eastern Mediterranean Regional Office (EMRO) to be high, approximately 4.3 million (15). WHO has classified HBV prevalence as low (< 2%), moderate (2% - 8%), and high (> 8%) (16). Low HBV prevalence areas include the United States, Eastern Europe, Australia, and New Zealand, moderate HBV prevalence areas include the Mediterranean countries, Japan, Central Asia, the Middle East, and Southern USA, and high HBV prevalence areas are placed in Southeast Asia, China, and sub-Saharan Africa (17). Iran, as an important country in the Middle East, has a moderate level of HBV prevalence (18). A systematic review by Alavian et al. on Iranian people revealed that more than one million people have HBV infection (19). The prevalence of HBV varies among pregnant women residing in EMRO countries and the Middle East, reported being 1.2% in Iran (20), 2.2% in Egypt (21), and 4% in Turkey (22).

Identifying the prevalence of HBV among pregnant women can have an important role in determining control and prevention policies so that the vertical transmission rate of the disease can be decreased in the region by implementing more extensive control programs. Comprehensive reviews studying the prevalence of HBsAg in EMRO and Middle Eastern countries have not investigated the prevalence among pregnant women. Lack of reliable information on the prevalence of HBsAg among pregnant women residing in these countries is noticeable. Therefore, a meta-analytic and review study in these countries seems useful. Motivated by the abovementioned reasons, the present study was conducted on cross-sectional studies published from 2000 to 2016 in order to determine the prevalence of HBsAg among pregnant women residing in EMRO and Middle Eastern countries.

2. Method

2.1. Sources of Data

We searched Pubmed, ISI Web of Science, ScienceDirect, Ovid, Scopus, and Google Scholar electronic databases for paper titles and/or abstracts in order to access papers published from January 1, 2000 to December 31, 2016. At this step, the number of papers found in each database and the final number of searched papers was recorded. We conducted searches using different combinations of keywords and MeSH terms including:

“epidemiology,” “prevalence,” “HBV,” “hepatitis b virus,” “HBsAg,” and “Pregnant women,” along with the names of the EMRO and Middle East countries, including: Afghanistan, Bahrain, Cyprus, Djibouti, Egypt, Iran, Iraq, Jordan, Kuwait, Lebanon, Libya, Morocco, Oman, Pakistan, Palestine, Qatar, Saudi Arabia, Somalia, Sudan, Syria, Tunisia, Turkey, United Arab Emirates, and Yemen.

Additionally, using the mentioned keywords in English and Persian, Iranian databases including Scientific Information Database, Iran Medex, Magiran, and Medlib, as well as other related international sources such as PakMediNet (comprehensive Pakistani database) and WHO Eastern Mediterranean Health Journal were included in our searches.

The sensitivity of the searches was examined by checking for duplicate papers. When the full-text of a paper was not available, we requested the paper from the author via email. In cases where the author did not answer the email, we used the abstract. Papers lacking the required information were excluded from the study.

2.2. Selecting the Studies

Full texts of English or Persian papers were included if they were cross-sectional and contained specific information on the prevalence of HBsAg among pregnant women residing in EMRO and Middle Eastern countries. At this step, studies conducted on the general population were also reviewed so that they would be included if any of their sub-groups consisted of pregnant women. The exclusion criteria were: (1) studies that were not cross-sectional and (2) studies that had not clearly reported the prevalence of HBsAg and only mentioned the general prevalence of hepatitis B (with respect to the aim of the study, i.e. investigating the prevalence of HBsAg among pregnant women). The names of authors or titles of journals had no effect on the selection of papers.

Journals had no effect on the selection of papers.

2.3. Data Extraction

Both authors evaluated the quality assessment of papers independently. First, the first author (M.B.), who was an epidemiologist, extracted the data in order to identify eligible studies. The other author (S.M.A.), who was an expert in hepatology and had not participated in the process of searching, conducted a detailed quality evaluation on the papers. At the next step and before the critical evaluation, the authors held a session on the research questions and in this session, all articles were assessed one by one by both authors and inclusion or exclusion of articles was specified. After the final evaluation, the authors recorded the selected studies and required data, i.e. name of the first author, publication year, country, sample size, the prevalence of HBsAg, and standard error (SE), and entered them
Malekifar P et al.

into the Excel software. SE was calculated using Cochran’s test.

2.4. Statistical Analysis

Heterogeneity was assessed based on Cochran’s Q-test results. However, since this test may fail to exactly discover true heterogeneity, it was complemented with Higgins and Thompson’s \( I^2 \). The command “metaprop” was then used to apply a fixed or random effects model based on the results and significance of the Cochran’s test results or a large \( I^2 \) value, respectively. By using metaprop, no studies with 0% or 100% proportions were excluded from the meta-analysis. Furthermore, study specific and pooled confidence intervals were always within admissible values and avoid confidence intervals exceeding the 0 to 1 range (23). Data aggregation and production of the pooled estimates were performed using the above-mentioned methods. Forest plots with descriptions of the findings were then developed to describe the results and calculate the point estimations and 95% confidence intervals (CIs).

3. Results

In the first step, 4725 papers were found based on titles and/or abstracts, 932 papers of which were potentially relevant to the aims of the study and selected. In the next step, 550 duplicate papers were excluded, leaving 382 papers related to the prevalence of HBV in EMRO and Middle Eastern countries. Based on the available data, 55 papers reporting the prevalence of HBV among pregnant women were selected. Due to the importance of papers’ quality evaluation, 5 papers lacking the inclusion criteria were excluded from the study, 4 of which were in the form of a short report or letter to the editor (24-27), and 1 had not clearly reported the prevalence of HBsAg among pregnant women, only mentioning the prevalence of HBsAg and HBV (28). At the end, 49 papers, which had clearly reported the prevalence of HBsAg among pregnant women, remained for the analysis (Figure 1). Data on HBsAg prevalence in pregnant women wasn’t found for other EMRO and Middle Eastern countries.

3.1. Characteristics of Studies

Generally, 49 papers were selected from 13 EMRO and Middle Eastern countries, reporting the prevalence of HBsAg among pregnant women, with the sample size of 89452. From among them, 2 studies had been conducted in Egypt (21, 29), 20 in Iran (30-49), 1 in Jordan (50), 1 in Libya (51), 1 in Oman (52), 3 in Pakistan (53-55), 1 in Jordan (50), 3 in Saudi Arabia (56-58), 3 in Sudan (59-61), 1 in Tunisia (62), 1 in Turkey (22, 63-72), 1 in the United Arab Emirates (52), and 1 in Yemen (73).

3.2. The Pooled Prevalence of HBsAg Among Pregnant Women Residing in EMRO and Middle Eastern Countries

Based on the available data from 13 countries with at least one included study, the highest and lowest prevalence of HBsAg among pregnant women was 10.8% for Yemen and 1% for Qatar (Table 1). In addition, the pooled prevalence of HBsAg in countries with at least 2 papers revealed that the prevalence of HBsAg among pregnant women was 1.35% (95% CI: 1.22 - 1.48) in Iran and 2.03% (95% CI: 1.74 - 2.37) in Pakistan, which were lowest rates after the mentioned prevalence for Qatar. The prevalence in countries with at least 2 papers is available in Table 2 and Figures 2 - 6. Furthermore, the geographic distribution of HBsAg prevalence in pregnant women of EMRO and Middle East countries was shown in Figure 7.

4. Discussion

The present study was conducted to determine the prevalence of HBsAg among pregnant women from EMRO and Middle East countries during 2000 - 2016. In this study, the minimum and maximum prevalence of HBsAg among pregnant women in the countries of the EMRO and the Middle East was 1% and 10.8% for Qatar and Yemen, respectively. In the literature review, the prevalence of HBsAg among pregnant women is different in various parts of the world. The prevalence among the African countries such as Ethiopia (3.8%) (74) as well as Nigeria (11.6% and 12.5%) (75, 76) and among the Western Pacific countries such as Taiwan (15.5%) (77), and China (5.49%) (78) is medium and high, while the European countries have an acceptable situation, in which the prevalence of HBsAg is much lower. The prevalence is low in European countries such as Germany (0.48%) (79), France (0.65%) (80), and England (0.9%) (81). The prevalence of HBsAg among pregnant women in the United States is different for different race: 6% among Asian women, 1% among African American women, 0.6% among non-Hispanic white women, and 0.1% among Hispanic women (3).
It is no doubt that hepatitis is still a global public health problem. For the first time in 2016, the World Health Assembly approved "the global health sector strategy on viral hepatitis in 2016 - 2020". The prospect of this strategy is the elimination of viral hepatitis as a public health concern. The global objectives of this strategy are to reduce viral infections by 90% and decrease mortality caused by viral hepatitis by 65% by the year 2030 (82). However, almost 600000 people die annually due to complications such as acute liver failure, cirrhosis, and liver cancer (12). According to the Center for Disease Control, lack of the post exposure immune prophylaxis, nearly 40% of the infants in the United States with mothers infected with HBV have chronic HBV infection and, finally, one out of every four infants die of the chronic liver diseases (83). In addition to the problems associated with HBV infection in infants, other small-scale complications can occur in infants and women. Greater incidence of low birth weight and prematurity has been reported among pregnant women with acute hepatitis B infections. Gestational diabetes, antepartum hemorrhage, and preterm delivery are higher among mothers with chronic infection than the general population (3),

Figure 1. Follow diagram of systematic review and meta-analysis of HBsAg prevalence in pregnant women of EMRO and Middle East regions

Records identified through database searching and other sources (n = 4725)

Unrelated/patients/ high risk groups excluded (n = 3793)

Title and/abstract screened (n = 932)

Duplicated studies excluded (n = 550)

Records on HBV prevalence (n = 382)

Not HBV prevalence in pregnant women (n = 328)

Full-text articles on HBV in pregnant women (n = 54)

Four brief report or editorial and one that wasn’t reported clearly HBsAg prevalence were excluded (n = 5)

Studies included in quantitative synthesis (meta-analysis) (n = 49)

Hepat Mon. 2018; 18(9):e58830.
while this problem can be more acute and widespread in less developed and non-developed countries with higher prevalence of infection among the pregnant women.

The safe and effective hepatitis B vaccine became commercially available in 1982 (84). In December 2006, 164 of the 193 countries in the World Health Organization included hepatitis B vaccination in their child-care program (82). According to the World Health Organization, the global vaccination coverage in the third injection was 84% in 2015 (82). The vaccination and increase in the number of people resistant to hepatitis B can reduce the burden of hepatitis in the society and, as a result, decrease its transmission to women of reproductive ages and, thus, to pregnant women. Studies in Asia have shown the effect of vaccination on reducing the prevalence of chronic infection and hepatocellular carcinoma among children (85-87). Another factor affecting the reduction of prevalence can be prevention strategies such as screening blood donations among the volunteers and quality control. In 2013, 97% of blood donors underwent screening and quality control. This screening had a positive effect on reducing transmission to the society. The decrease in the unsafe injection from 39% to 5% from 2000 to 2010 in the world can also be an effective factor for the prevalence decline (82). However, hepatitis B is still a public health problem with high and medium prevalence in Asian countries. On the other hand, many people with chronic infection are asymptomatic until the cirrhosis or final stages of the liver disease and studies show that many people with chronic infection are unaware of the disease (88-90).

In view of the fact that nearly 40% - 50% of carriers of hepatitis B are infected through the mother-to-child way, (91) one of the mother-to-child transmission prevention strategies can be screening pregnant women to identify those with hepatitis B and, as a result, strategies such as hepatitis B and immunoglobulin vaccination at birth.
2004, the US Preventive Services suggested the screening of pregnant women in the first prenatal visit (92). In American and European countries, infection in the society is low (3, 79-81); however, by screening, the pregnant women had more opportunities for preventing this infection among their children. It seems that in less- and non-developed countries with high and medium prevalence, screening has an important role in reducing infection transmitted from mother to newborn. Studies have demonstrated that the infection is higher among immigrants, particularly those from endemic areas, than the native population (3, 79). It seems that this group of people should be considered as high-risk groups in the studies on pregnant women. Since vaccination during pregnancy has no risk to the mother and fetus, it can be one of the strategies to deal with high-risk pregnant women (93).

However, in addition to the injection of vaccine and immunoglobulin into infants at birth, one of the ways to
control the disease transmission is to use drugs such as telbivudine, lamivudine, and tenofovir, as a drug prevention strategy, among pregnant women who are diagnosed with the disease in screening. This strategy can prevent

**Figure 5.** Forest plot of HBsAg prevalence in pregnant women from Sudan

**Figure 6.** Forest plot of HBsAg prevalence in pregnant women from Turkey
the viral transmission to children without adverse effects on children and mothers (94). Since 3% - 13% of the children with infected mothers fail in active and passive preventions (13, 14), measures such as maternal screening and drug therapy for reducing the risk of transmission and incidence of chronic disease in children can be the possible ways to achieve the goals of the World Health Organization in terms of reducing the incidence and mortality rate of this disease (95).

4.1. Limitations and Strengths

The first limitation of this study was the limited number of studies compared to the number of countries in the region. In order to solve this problem, we also used several studies performed on the prevalence of HBsAg in the general population in which pregnant women were studied as a subgroup. The second limitation was that we attempted to assess the prevalence of HBsAg among pregnant women in published papers and conference abstracts and grey literature were excluded, which should be considered in future studies. The third limitation was a lack of reporting the separated prevalence of HBsAg among pregnant women in terms of age, making it impossible to report the prevalence in different age groups. The fourth limitation was that we searched the English and Persian literatures, however, not the Arabic literature, which should be considered in future studies. As the last limitation, data on HBsAg prevalence in pregnant women wasn’t found for some EMRO and Middle Eastern countries that should be considered in future studies. The most important strength of the present study was the high sensitivity of searching to find the relevant studies. We tried to use all the relevant keywords for searching.

4.2. Conclusion

Based on the WHO classification of HBV prevalence, the available data on the prevalence of HBsAg in pregnant women of EMRO and Middle East countries showed that there was a different pattern of HBsAg prevalence in studied countries. Low, moderate, and high prevalence of HBsAg was observed for EMRO and Middle East countries during 2000 - 2016. Although there were countries with low prevalence of HBsAg, the lowest frequency in our study was higher than the reported prevalence in developed countries. Increasing the rate of Hepatitis B vaccination is suggested to reduce the prevalence of HBsAg in EMRO and Middle East countries, especially in countries with high prevalence of HBsAg. Additionally, screening of women during the pregnancy in all studied countries is suggested.
Footnote

Funding/Support: There is no funding source.

References

1. Lee WM. Hepatitis B virus infection. N Engl J Med. 1997;337(24):1733-45. doi:10.1056/NEJM199712113372406. [PubMed: 9337000].
2. Previsani NLD. Hepatitis B. WHO/CDS/CSR/STD/2002:2. Hepatitis B. 2002.
3. Jonas MM. Hepatitis B and pregnancy: an underestimated issue. Liver Int. 2009;29 Suppl 1:133-9. doi:10.1111/j.1478-3231.2008.01933.x. [PubMed: 19207977].
4. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11(2):97-107. doi:10.1046/j.1365-2893.2003.00487.x. [PubMed: 14996143].
5. Sinha S, Kumar M. Pregnancy and chronic hepatitis B virus infection. Hepatol Res. 2010;40(1):31-48. doi:10.1111/j.1872-034X.2009.00597.x. [PubMed: 19488694].
6. Ghosh M, Mandal S, Dutta S, Saha MK. Detection of hepatitis B virus infection: A systematic review. World J Hepatol. 2015;7(23):2482-91. doi:10.4254/wjh.v7.i23.2482. [PubMed: 26483870]. [PubMed Central: PMC4606204].
7. Okada K, Kamiyama I, Inomata M, Imai M, Miyakawa Y. e antigen and anti-e in the serum of asymptomatic carrier mothers as indicators of positive and negative transmission of hepatitis B virus to their infants. N Engl J Med. 1976;294(14):746-9. doi:10.1056/NEJM197604022941402. [PubMed: 9438694].
8. Beasley RP, Trepo C, Stevens CE, Szmuszen W. The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol. 1977;105(2):94-8. [PubMed: 835566].
9. Xu ZY, Liu CB, Francis DP, Purcell RH, Gun ZL, Duan SC, et al. Prevention of perinatal acquisition of hepatitis B virus carriage using vaccine: preliminary report of a randomized, double-blind placebo-controlled and comparative trial. Pediatrics. 1985;76(5):733-8. [PubMed: 3903646].
10. Stevens CE, Toy PT, Tong MJ, Taylor PE, Vyas GN, Nair PV, et al. Prevention of perinatal acquisition of hepatitis B virus carriage using vaccine: preliminary report of a randomized, double-blind placebo-controlled and comparative trial. Pediatrics. 1985;76(5):733-8. [PubMed: 3903646].
11. Xia ZY, Liu CB, Francis DP, Purcell RH, Gun ZL, Duan SC, et al. Prevention of perinatal acquisition of hepatitis B virus carriage using vaccine: preliminary report of a randomized, double-blind placebo-controlled and comparative trial. Pediatrics. 1985;76(5):733-8. [PubMed: 3903646].
12. World Health Organization. Prevention and control of viral hepatitis infection: framework for global action. 2012. Geneva: World Health Organization; 2015.
13. World Health Organization. Hepatitis B vaccines. Wkly Epidemiol Rec. 2009;84(40):405-9. [PubMed: 19887078].
14. Borja G, Carleo MA, Gaeta GB, Gentile I. Hepatitis B in pregnancy. World J Gastroenterol. 2012;18(34):4677-83. doi:10.3748/wjg.v18.i34.4677. [PubMed: 23002336]. [PubMed Central: PMC3442205].
15. Han GR, Cao MK, Zhao W, Jiang HK, Wang CM, Bai SF, et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol. 2011;55(6):1215-21. doi:10.1016/j.jhep.2010.09.032. [PubMed: 20703206].
16. World Health Organization. The growing threats of hepatitis B and C in the Eastern Mediterranean Region: a call for action. 2009. Available from: http://applications.emro.who.int/docs/EM_RC56_3_en.pdf.
17. World Health Organization. Hepatitis B. 2015. Available from: http://www.who.int/mediacentre/factsheets/fs204/en/.
18. Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis. 2010;14(1):21-41. viii. doi:10.1016/j.cld.2009.09.009. [PubMed: 20123436].
19. Alavian SM, Hajarizadeh B, Ahmadzad-Asl M, Kabir A, Bagheri-Lankarani K. Hepatitis B virus infection in Iran: A systematic review. Hepat Mon. 2008;8(4):281-94.
20. Moghaddasifar J, B. Lankarani K, Moosazadeh M, Afshari M, Malary M. Prevalence of hepatitis B virus infection among pregnant women in Iran: A systematic review and meta-analysis. Iran J Cancer Prev. 2016;9(6). doi:10.17795/jcp-3703.
21. Abo-Salem MES, Mahrous OAE, El-Shaarawy AA, Mohamed HM, Yehia SAS. Seroprevalence of hepatitis B virus among pregnant women attending maternal and child health centres in Shebin El-Kom district (Menoufia governorate). Menoufia Med J. 2014;27(4):847-52. doi:10.4013/mn-2009.149805.
22. Ayniqulu A, Ayniqulu O, Tarik A, Aydin M, Altunok ES. HBsAg, Anti-HBs and Anti-HCV seropositivity rates among pregnant women Attending a University Hospital in Zonguldak. Viral Hepat. 2015;21(1):31-4. doi:10.4234/VH.v11.i2.27792.
23. Nyaga VN, Arbyo M, Aerts M. Metaprop: a Stata command to perform meta-analysis of binomial data. Arch Public Health. 2014;72(1):39. doi:10.1186/s12960-014-0056-6. [PubMed: 25810908]. [PubMed Central: PMC4373114].
24. Altinbas S, Erdogan M, Danisman N. The seroprevalences of HBs Ag and anti-HCV in pregnant women in Ankara. Arch Gynecol Obstet. 2010;281(2):371. doi:10.1007/s00404-009-1145-6. [PubMed: 19927206].
25. Araz NC, Dikensoy E. Seroprevalence of hepatitis B among pregnant women in southern Turkey. J Med Assoc. 2010;84(2):576-7. [PubMed: 21175171].
26. Ahmad I. Prevalence of hepatitis B and C viral infection among pregnant women in Peshawar, Pakistan. Hepat Mon. 2010;6(6). e63183. doi:10.5812/hepatmon.36383. [PubMed: 27630725]. [PubMed Central: PMC5014001].
27. Yavuz U, Cevat C, Alaaddin B. Seroprevalence of hepatitis B virus among pregnant women in Northern Turkey. Hepat Mon. 2009;9(2):2146-9.
28. Ghanghro AA, Ghanghro L. High prevalence of hepatitis C and hepatitis B infection among pregnant women and their blood donors District Naushahr Feroze, Pakistan 2014. J Emerg Med Trauma Acute Care. 2016;2(2):32. doi:10.5339/jemtac.2016.icepq.32.
29. Zahran KM, Badary MS, Agban MN, Abdel Aziz NH. Pattern of hepatitis virus infection among pregnant women and their newborns at the Women's Health Center of Assuit University, Upper Egypt. Int J Gynecol Obstet. 2010;111(1):7-10. doi:10.1016/j.ijgo.2010.06.003. [PubMed: 20708888].
30. Afzali H, Momen Heravi M, Moravejia SF, Poorrahnama M. Prevalence of hepatitis B surface antigen in pregnant women in Beheshti Hospital of Kasahan, Isfahan. Iran Red Crescent Med J. 2015;17(7). e20598. doi:10.5812/ircmj.20598v2. [PubMed: 26421168]. [PubMed Central: PMC4548256].
31. Ahmadi M, Toghyani R, Shahidi S, Izadi M, Merasi MR, Agdak P, et al. Prevalence of HBsAg and high-risk behaviors in pregnant women reffering to Urban Health Centers in Isfahan province. Iran J Nurs Midwifery Res. 2016;11(6):47-54. doi:10.5812/ijnmr.2016.61112. [PubMed: 22039379]. [PubMed Central: PMC5203299].
32. Aminzadeh Z, Gachkar L, Gentle I. Hepatitis B in pregnancy: a systematic review in pregnant women Rafsanjan in the year 2003. Journal of Rafsanjan University of Medical Sciences. 2004;3(2):126-31. Persian.
33. Bayani M, Biazzar T, Bayani F, Siadati S. The effect of hepatitis B vaccination at birth on reducing the prevalence of hepatitis B surface antigen among rural pregnant women in Babol, Iran. J Babol Univ Med Sci. 2016;20(1):7-10.
34. Cheraghali F, Yazarloo S, Behnampour N, Azarhoush R. Frequency of HBsAg in pregnant women in Gorgan, Iran. J Gorgan Univ Med Sci. 2016;14(2):8-16. Persian.
36. Kheiri L, Mukandvi S. The prevalence of hepatitis B surface antigen (HBsAg) and its influencing factors in pregnant women referring to Healthcare Centers of Dehloran, Iran in 2011-2012. J Midwifery Reprod Health. 2015;3(4):224-9.
37. Mirghafourvand M, Rafie A, Montazam SH. [Study of prevalence and contributing factors of hepatitis B among pregnant women referred to laboratory of health center of Bonab]. J Urmia Nurs Midwifery Fac. 2007;3(1):320-31. Persian.
38. Mobin AR, Mohammadian F, Mazloomzadeh S, Esmaeilzadeh A, Sorouri Zanjani R, Savabi S, SoleimaniSorouri Zanjani R, Savabi S, SoleimaniSorouri Zanjani R, Savabi S, Soleimani. [Prevalence of Hepatitis B virus among pregnant women referred to healthcare centers of Zanjani]. Zanjan Univ Med Sci J. 2004;22(9):96-104. Persian.
39. Mohamad Jafari R, Saadati N, Vaziri S, Soranian A. [Frequency of positive HBsAg cases in pregnant women referred to health centers of Ahvaz]. Payesh Q. 2004;3(3):237-43. Persian.
40. Mohebbi SR, Sanati A, Cheraghipour K, Rostami Nejad M, Shalmani HM, Zali MR. Hepatitis C and hepatitis B virus infection: epidemiology and risk factors in a large cohort of pregnant women: epidemiology and risk factors in a large cohort of pregnant women in Lorestan, West of Iran. Hepat Mon. 2011;11(9):736-9. doi: 10.5812/strainov.173543X.749. [PubMed: 22252577]. [PubMed Central: PMC3224534].
41. Motamedifar M, Amini E, Talezadeh Shirazi P, Sarvari J. The prevalence of HBsAg and HBsAb among pregnant women re-ferring to Zeinabiyeh Hospital, Shiraz Iran. Shiraz E Med J. 2002;3(4):217-96. Persian.
42. Motazakker M, Shokat Nagadeh M, Khalili F, Shayeri M. [Hepatitis B virus infection among pregnant women attending health care centers of Urmia]. J Uilan Univ Med Sci. 2014;23(89):45-50. Persian.
43. Sahaf F, Tanomand A, Montazam H, Sany A. Seroprevalence of hepatitis C, hepatitis B and HIV and co-infection among pregnant women: A retrospective study in 2006 at Malekan city, Iran. Res J Med Sci. 2007;2(1):138-41.
44. Salimi S, Alijahan R, Nakhostin B, Hazzati S. [Prevalence of HBsAg cases and its associated factors in pregnant women referred to health centers of ardabil district in 2009]. J Health. 2014;5(3):244-58. Persian.
45. Sharifi Mood B, Keykhah F, Salehi M, Kohpayeh HR, Alavi Nayini R, et al. Prevalence of hepatitis B surface antigen in pregnant women in Zahedan, Iran. Hepat Mon. 2004;4(8):161.
46. Sharifi M, Asefzade M, Laloiua F, Alijahan R, Hazzati S. [Prevalence of HBsAg carriers in pregnant women in Qazvin in 2000-2001]. J Qazvin Univ Med Sci. 2006;10(3):38-72. Persian.
47. Shohghi A, Nabavi SM, Alaviani SM, Kolifarhood G, Goya MM, Namazi HR, Alavi Nayini R, et al. Prevalence of hepatitis B surface antigen in pregnant women: a cross-sectional survey in Iran. Int J Prev Med. 2014;4(Suppl 3):S213-8. [PubMed: 26622992]. [PubMed Central: PMC4615415].
48. Tabasi Z, Morhasmeyi M, Mozaffar SGA, Ghafouri L. [HBsAg in parturients referring to gynecologic clinics in Kashan, 2002]. Payesh Q. 2003;1(7):335-41. Persian.
49. Mobijian M, Srour AM. [The prevalence rate of hepatitis B virus and hepatitis C virus in pregnant Sudanese women. Virol J. 2007;4:104. doi: 10.1186/1743-422X-4-104. [PubMed: 17958904]. [PubMed Central: PMC2169999].
50. Abuelgasim MH, Baraka MKB. Prevalence of hepatitis B infection among Pregnant WOMEN at Khartoum Teaching Hospital, Sudan. East Mediterr Health J. 2015;21(9):58-63.
51. Elsheikh RM, Daak AA, Elsheikh MA, Karsany MS, Adam I. Hepatitis B virus and hepatitis C virus in pregnant women. Virol J. 2007;4:104. doi: 10.1186/1743-422X-4-104. [PubMed: 17958904]. [PubMed Central: PMC2169999].
52. Al Awaidy S, Abu-Elyazeed R, Al Hosani H, Al Mulla A, Al Basaidey S, Al Amiry A, et al. Sero-epidemiology of hepatitis B virus and hepatitis C virus in pregnant women from the rural Southeastern Turkey. Afr J Microbiol Res. 2011;5(23):3942-5. doi: 10.5897/ajmr11.675. [PubMed: 2572880].
53. Guckan R, Kilinc C, Gozdemir E. HBSAG, Anti Hbs, Anti -HCV and Anti -HIV seroplevalence in pregnant women living in Rize region. Dicle Med J. 2013;40(2):254-7. doi: 10.5796/diclemedj.0923.2013.02.0265.
54. Deveci O. Investigation of intrauterine transmission of Hepatitis B Virus to children from HBsAg-positive pregnant women. Microbiol Infect Dis. 2011;1:14-6. doi: 10.57999/ajinhs.02.2011.01.0004.
55. Dogan K, Guraslan H, Ozel G, Aydan Z, Yasar L. [Seroprevalence rates of Toxoplasma gondii, rubella, cytomegalovirus, syphilis, and hepatitis B, seroprevalence rates in the pregnant population in Istanbul]. Turk J Parasitol Derg. 2004;34(4):228-33. Turkish. doi: 10.5132/tipd.2004.3435. [PubMed: 2572880].
56. Gonen I. The frequency of HBV and HCV in pregnant women in rural areas. Viral Hepat Dermis. 2011(72).
57. Guckan R, Kilinc C, Gozdemir E. HBSAG, Anti Hbs, Anti -HCV and Anti -HIV seroprevalence in pregnant women living. Asian Pac J Curr Med Sci Health. 2015;11:1-9.
58. Karaca C, Karaca N, Usta T. The frequencies of Hepatitis B, C, D virus infection in the pregnant population and the rate of perinatal transmission of Hepatitis C virus. Akademik Gastroenteroloji Dergisi. 2003;2:222-2.
59. Evrigen O, Alsakal M, Melek I, Onlen Y, Sahabattin O. Seropositivity of hepatitis B and hepatitis C in women who were admitted to Hatay Maternityand Children’s Hospital. Viral Hepat Dermis. 2010;25(2).
60. Tosun SY, Erensos Y, Ozacar T, Yuceselgin S, Bİlgic A. The investigation and follow-up of pregnant women and their children for hepatitis virus infections. Türk Mikrobiyol Cem Derg. 2001;33:553-9.
61. Yavuzcan A, Altunbas A, Altunbas , A. An unexpected low hepatitis B seroprevalence in pregnant women from the rural Southeastern Turkey. Afr J Microbiol Res. 2011;5(23):3942-5. doi: 10.5897/ajmr11.675. [PubMed: 2572880].
62. Furuncuoglu Y, Bolukbas FF, Bolukbas C, Torun P, Ozturk R. Changes in the prevalence of HBV infection in pregnant women in Turkey between 1995 and 2015: a 20-year evaluation. Postgrad Med J. 2016;92(1091):550-1. doi: 10.1136/postgradmedj-2015-133876. [PubMed: 26941270].
63. Malekifar Pet al. Hepat Mon. 2018;18(9):e58830.
Hepatitis B

73. Murad FA, Babiker SM, Gasim GI, Rayis DA, Adam I. Epidemiology of hepatitis B and hepatitis C virus infections in pregnant women in Sana'a, Yemen. BMC Pregnancy Childbirth. 2013;13:227. doi: 10.1186/1471-2393-13-227. [PubMed: 23758990]. [PubMed Central: PMC3684507].

74. Ramos JM, Toro C, Reyes F, Amor A, Gutierrez F. Seroprevalence of HIV, HBV, HTLV-I and Treponema pallidum among pregnant women in a rural hospital in Southern Ethiopia. J Clin Virology. 2011;51(1):83-5. doi: 10.1016/j.jcv.2011.01.010. [PubMed: 21339966].

75. Harry TO, Bajani MD, Moses AE. Hepatitis B virus infection among pregnant women in Shenyang, China. Virol J. 2013;10(1):18254978. [PubMed Central: PMC2275262].

76. Lin CC, Hsieh HS, Huang YJ, Huang YL, Ku MK, Hung HC. Hepatitis B virus infection among pregnant women and their infants in Shenyang, China. Virol J. 2013;10(1):18254978. [PubMed Central: PMC2275262].

77. Lin K, Vickery J. Screening for hepatitis B infection in pregnant women: evidence for the U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med. 2009;150(12):874-6. [PubMed: 19528566].

78. Malekifar P et al. Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta-analysis. Korean J Hepatol. 2011;17(1):1-8. doi: 10.3350/kjhep.2011.17.1.1. [PubMed: 21494071]. [PubMed Central: PMC3104622].

79. Lin YC, Chang MH, Ni YH, Hsu HY, Chen DS. Long-term immunogenicity and efficacy of universal hepatitis B virus vaccination in Taiwan. J Infect Dis. 2003;187(3):334-8. doi: 10.1086/345871. [PubMed: 12508157].

80. Lee CI, Ko YC. Hepatitis B vaccination and hepatocellular carcinoma in Taiwan. Pediatrics. 1997;99(3):331-3. doi: 10.1542/peds.99.3.331.

81. Lee CI, Ko YC. Hepatitis B vaccination and hepatocellular carcinoma in children. Taiwan Childhood Hepatitis Study Group. N Engl J Med. 1997;336(26):1855-9. doi: 10.1056/NEJM199706263362602. [PubMed: 9197211].

82. Malekifar P et al. Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta-analysis. Hepatology. 2016;63(1):319-33. doi: 10.1002/hep.28302. [PubMed: 26565396].
Table 1. The Description of Available Data in EMRO and Middle East That Met Our Eligibility Criteria

| Countries          | Authors’ Names            | Pub. Year | Samples Size | HBsAg Positive, No | HBsAg Prevalence, % |
|--------------------|---------------------------|-----------|--------------|--------------------|---------------------|
| Egypt (E and M)    | Abo-Salem MES (21)        | 2014      | 397          | 9                  | 2.3                 |
|                    | Zahran KM (29)            | 2010      | 500          | 20                 | 4                   |
| Iran (E and M)     | Afzali H (30)             | 2015      | 768          | 12                 | 1.56                |
|                    | Ahmadi M (35)             | 2011      | 1078         | 5                  | 0.5                 |
|                    | Aminzadeh Z (32)          | 2004      | 600          | 8                  | 1.3                 |
|                    | Bayani M (33)             | 2016      | 1065         | 2                  | 0.18                |
|                    | Chevaghali F (34)         | 2012      | 1553         | 15                 | 1                   |
|                    | Ravosi A (35)             | 2015      | 1057         | 17                 | 1.6                 |
|                    | Kheiri L (36)             | 2015      | 850          | 5                  | 0.59                |
|                    | Mirghaforvand M (37)      | 2007      | 187          | 6                  | 3.2                 |
|                    | Mobaien AR (38)           | 2014      | 1317         | 5                  | 0.4                 |
|                    | Mohammad Jafari R (39)    | 2005      | 120          | 2                  | 1.7                 |
|                    | Mohebbi SR (40)           | 2011      | 827          | 6                  | 0.7                 |
|                    | Motamedifar M (41)        | 2012      | 250          | 3                  | 1.2                 |
|                    | Motazakker M (42)         | 2014      | 368          | 3                  | 0.8                 |
|                    | Sahafi F (43)             | 2007      | 680          | 16                 | 2.5                 |
|                    | Salimi S (44)             | 2014      | 9321         | 159                | 1.7                 |
|                    | Sharifi Mood B (45)       | 2004      | 200          | 13                 | 6.5                 |
|                    | Sharifi M (46)            | 2006      | 323          | 11                 | 3.4                 |
|                    | Shogahi A (47)            | 2014      | 5261         | 64                 | 1.21                |
|                    | Tabasi Z (48)             | 2003      | 2000         | 7                  | 0.35                |
|                    | Mojibian M (49)           | 2001      | 1904         | 16                 | 0.84                |
| Jordan (E and M)   | Batayneh N (50)           | 2002      | 1000         | 43                 | 4.3                 |
| Libya (E and M)    | El Magrabe H (51)         | 2010      | 1500         | 23                 | 1.5                 |
| Oman (E and M)     | Al Awaidy S (52)          | 2006      | 604          | 43                 | 7.1                 |
| Pakistan (E)       | Sabir R (53)              | 2013      | 5772         | 90                 | 1.74                |
|                    | Asia B (54)               | 2008      | 2439         | 53                 | 2.2                 |
|                    | Mehnaz A (55)             | 2002      | 245          | 8                  | 3.26                |
| Qatar (E and M)    | Al Awaidy S (52)          | 2006      | 495          | 5                  | 1                   |
| Saudi Arabia (E and M) | Al Awaidy S (52)   | 2006      | 495          | 5                  | 1                   |
| Sudan (E)          | Elsheikh RM (65)          | 2007      | 728          | 41                 | 5.6                 |
|                    | Osman AMM (66)            | 2014      | 396          | 20                 | 5.1                 |
| Tunisia (E)        | Hannachi N (62)           | 2009      | 2303         | 92                 | 4                   |
| Turkey (M)         | Anyioglu A (22)           | 2015      | 1084         | 43                 | 4                   |
|                    | Balik G (63)              | 2013      | 5894         | 338                | 5.7                 |
|                    | Deveci O (64)             | 2011      | 1570         | 45                 | 2.9                 |
|                    | Dogan K (65)              | 2014      | 1450         | 18                 | 1.2                 |
|                    | Goren I (66)              | 2011      | 1028         | 34                 | 3.3                 |
|                    | Guvcan R (67)             | 2016      | 5540         | 50                 | 0.9                 |
|                    | Karaca C (88)             | 2003      | 460          | 22                 | 4.7                 |
| Study Location | Year | Study Code | Cases | Controls | Hepatitis A Virus (Hepatitis A) |
|----------------|------|------------|-------|----------|--------------------------------|
| Evirgen O (69) | 2010 | 12969 | 203 | 1.6 |
| Tosun S (70) | 2001 | 760 | 32 | 4.2 |
| Yavuzcan A (71) | 2011 | 473 | 7 | 1.47 |
| Furuncuoglu Y (72) | 2016 | 7605 | 114 | 1.5 |
| United Arab Emirates (E and M) | | | | |
| Al Awaidy S (52) | 2006 | 595 | 9 | 1.5 |
| Yemen (E and M) | | | | |
| Murad IA (73) | 2013 | 400 | 43 | 10.8 |

*E: EMRO countries; M: Middle East countries; E & M: All countries from two regions.